title: Microsphere-based drug releasing scaffolds for inducing osteogenesis of human mesenchymal stem cells in vitro.
abstract: In this study, in vitro osteogenesis was successfully achieved in human mesenchymal stem cells (hMSCs) by controlled release of the osteogenesis-inducing drugs dexamethasone, ascorbic acid (AA) and beta-glycerophosphate (GP) from poly(lactic-co-glycolic acid) (PLGA) sintered microsphere scaffolds (SMS). We investigated the osteogenesis of human MSCs (hMSCs) on dexamethasone laden PLGA-SMS (PLGA-Dex-SMS), and dexamethasone, AA and GP laden PLGA-SMS (PLGA-Com-SMS). hMSCs cultured on the microsphere systems, which act as drug release vehicles and also promote cell growth/tissue formation-displayed a strong osteogenic commitment locally. The osteogenic commitment of hMSCs on the scaffolds were verified by alkaline phosphatase (ALP) activity assay, calcium secretion assay, real-time PCR and immunohistochemistry analysis. The results indicated hMSCs cultured on PLGA-Com-SMS exhibited superior osteogenic differentiation owing to significantly high phenotypic expression of typical osteogenic genes-osteocalcin (OC), type I collagen, alkaline phosphatase (ALP), and Runx-2/Cbfa-1, and protein secretion of bone-relevant markers such as osteoclast and type I collagen when compared with PLGA-Dex-SMS. In conclusion, by promoting osteogenic development of hMSCs in vitro, this newly designed controlled release system opens a new door to bone reparation and regeneration.
authors.affiliation: School of Materials Science and Engineering, South China University of Technology, Guangzhou 510641, China.
authors.forename: Xuetao
authors.initials: X
authors.lastname: Shi
authors.forename: Yingjun
authors.initials: Y
authors.lastname: Wang
authors.forename: Rohan R
authors.initials: RR
authors.lastname: Varshney
authors.forename: Li
authors.initials: L
authors.lastname: Ren
authors.forename: Yihong
authors.initials: Y
authors.lastname: Gong
authors.forename: Dong-An
authors.initials: DA
authors.lastname: Wang
mesh_terms: D001205:Ascorbic Acid / Q000008:administration & dosage / Q000494:pharmacology; D001672:Biocompatible Materials / Q000737:chemistry; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D003692:Delayed-Action Preparations / Q000138:chemical synthesis / Q000494:pharmacology; D003907:Dexamethasone / Q000008:administration & dosage / Q000494:pharmacology; D004337:Drug Carriers / Q000138:chemical synthesis*; D005994:Glycerophosphates / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D019344:Lactic Acid / Q000737:chemistry; D059630:Mesenchymal Stem Cells / Q000187:drug effects* / Q000378:metabolism; D008863:Microspheres; D010012:Osteogenesis / Q000187:drug effects*; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D023822:Tissue Engineering / Q000379:methods*; D054457:Tissue Scaffolds / Q000737:chemistry*
chemical_list: D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D005994:Glycerophosphates; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D003907:Dexamethasone; D001205:Ascorbic Acid; C031463:beta-glycerophosphoric acid